Germany licenses Oralair for children's grass allergies
This article was originally published in Scrip
Executive Summary
Germany's Paul-Ehrlich Institute has granted a paediatric marketing authorisation for Stallergenes' Oralair Grasses sublingual tablet therapy for desensitisation to grass pollens in children five to 17 years old. It was licensed for adult use in Germany in June last year, and Germany is acting as the reference member state in the EU's mutual recognition procedure for both the adult and child indications.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.